S. Yzer

Type

Articles (5) Reviews (1)

Co-author

Date

Source

Keyword

disease (3) Treatment (3) Photochemotherapy (3) Patients (3) Human beings (3) Patients (3) disease (3) age (2) Weights and measures (2) Trials (2) Serum (2) Fluorescence angiography (2) Evidence (2) Age (2) Verteporfin (2) Use (2) Age (2) world (1) therapy (1) safety (1) risk (1) quality of life (1) protein (1) association (1) monitoring (1) membrane (1) loss (1) leakage (1) laser (1) interest (1)

Documents written by S. Yzer (5) | is about S. Yzer (0)

Perspectives and Update on the Global Shortage of Verteporfin (Visudyne).
M.J. Sirks et al.
Central serous chorioretinopathy: An evidence-based treatment guideline.
HMA Feenstra et al.
High Levels of C-Reactive Protein with Low Levels of Pentraxin 3 as Biomarkers for Central Serous Chorioretinopathy.
E. Bousquet et al.
Increasing evidence for the safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy.
HMA Feenstra et al. (Mar 1, 2023)
Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy.
A. Matet et al. (Nov 19, 2020)